Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma

被引：21

作者：

Bhatt, Vijaya Raj ^{[1
]}

Vose, Julie M. ^{[1
]}

机构：

[1] Univ Nebraska Med Ctr, Dept Internal Med, Div Hematol Oncol, Omaha, NE 68198 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2014年 / 28卷 / 06期

关键词：

Non-Hodgkin lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Peripheral T-cell lymphoma; Autologous hematopoietic stem cell transplantation; Allogeneic hematopoietic stem cell transplantation; HIGH-DOSE THERAPY; PROGRESSION-FREE SURVIVAL; INTERNATIONAL PROGNOSTIC INDEX; DETUDE DES LYMPHOMES; RITUXIMAB MAINTENANCE THERAPY; ADVANCED FOLLICULAR LYMPHOMA; BONE-MARROW-TRANSPLANTATION; LONG-TERM SURVIVAL; PHASE-II TRIAL; T-CELL;

D O I：

10.1016/j.hoc.2014.08.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Up-front rituximab-based chemotherapy has improved outcomes in non-Hodgkin lymphoma (NHL); refractory or relapsed NHL still accounts for approximately 18,000 deaths in the United States. Autologous hematopoietic stem cell transplantation (SCT) can improve survival in primary refractory or relapsed aggressive NHL and mantle cell lymphoma and in relapsed follicular or peripheral T-cell lymphoma. Autologous SCT as a consolidation therapy after first complete or partial remission in high-risk aggressive NHL, mantle cell lymphoma, and peripheral T-cell lymphoma may improve progression-free survival. Allogeneic SCT offers a lower relapse rate but a higher nonrelapse mortality resulting in overall survival similar to autologous SCT.

引用

页码：1073 / +

页数：24

共 116 条

[1] Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance [J].

Ahmadi, T. ;

McQuade, J. ;

Porter, D. ;

Frey, N. ;

Loren, A. W. ;

Goldstein, S. C. ;

Svoboda, J. ;

Stadtmauer, E. ;

Schuster, S. J. ;

Nasta, S. D. .

BONE MARROW TRANSPLANTATION, 2012, 47 (08) :1082-1086

[2] Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial [J].

Ahn, Jae-Sook ;

Yang, Deok-Hwan ;

Jung, Sung-Hoon ;

Chae, Yee Soo ;

Sohn, Sang Kyun ;

Yhim, Ho-Young ;

Kwak, Jae-Yong ;

Lee, Se-Ryeon ;

Kim, Yeo-Kyeoung ;

Kim, Hyeoung-Joon ;

Lee, Je-Jung .

ANNALS OF HEMATOLOGY, 2013, 92 (06) :789-797

[3] Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients [J].

Akhtari, Mojtaba ;

Bhatt, Vijaya Raj ;

Tandra, Pavan Kumar ;

Krishnamurthy, Jairam ;

Horstman, Heidi ;

Dreessen, Amy ;

Chen, Pei Xian ;

Armitage, James O. .

CANCER BIOLOGY & THERAPY, 2013, 14 (12) :1077-1088

[4] Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma [J].

Andersen, Niels S. ;

Pedersen, Lone B. ;

Laurell, Anna ;

Elonen, Erkki ;

Kolstad, Arne ;

Boesen, Anne Marie ;

Pedersen, Lars M. ;

Lauritzsen, Grete F. ;

Ekanger, Roald ;

Nilsson-Ehle, Herman ;

Nordstrom, Marie ;

Freden, Susanne ;

Jerkeman, Mats ;

Eriksson, Mikael ;

Vaart, Jaan ;

Malmer, Beatrice ;

Geisler, Christian H. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4365-4370

[5]

[Anonymous], ASH ANN M

[6] Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma [J].

Arcaini, L. ;

Montanari, F. ;

Alessandrino, E. P. ;

Tucci, A. ;

Brusamolino, E. ;

Gargantini, L. ;

Cairoli, R. ;

Bernasconi, P. ;

Passamonti, F. ;

Bonfichi, M. ;

Zoli, V. ;

Bottelli, C. ;

Calatroni, S. ;

Troletti, D. ;

Merli, M. ;

Pascutto, C. ;

Majolino, I. ;

Rossi, G. ;

Morra, E. ;

Lazzarino, M. .

ANNALS OF ONCOLOGY, 2008, 19 (07) :1331-1335

[7] How I treat patients with diffuse large B-cell lymphorna [J].

Armitage, James O. .

BLOOD, 2007, 110 (01) :29-36

[8] ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES: A CONTINUING MEDICAL EDUCATION SERIES The aggressive peripheral T-cell lymphomas: 2013 [J].

Armitage, James O. .

AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (10) :910-918

[9] Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? [J].

Bacher, Ulrike ;

Klyuchnikov, Evgeny ;

Le-Rademacher, Jennifer ;

Carreras, Jeanette ;

Armand, Philippe ;

Bishop, Michael R. ;

Bredeson, Christopher N. ;

Cairo, Mitchell S. ;

Fenske, Timothy S. ;

Freytes, Cesar O. ;

Gale, Robert Peter ;

Gibson, John ;

Isola, Luis M. ;

Inwards, David J. ;

Laport, Ginna G. ;

Lazarus, Hillard M. ;

Maziarz, Richard T. ;

Wiernik, Peter H. ;

Schouten, Harry C. ;

Slavin, Shimon ;

Smith, Sonali M. ;

Vose, Julie M. ;

Waller, Edmund K. ;

Hari, Parameswaran N. .

BLOOD, 2012, 120 (20) :4256-4262

[10] Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial [J].

Briones, Javier ;

Novelli, Silvana ;

Garcia-Marco, Jose A. ;

Tomas, Jose F. ;

Bernal, Teresa ;

Grande, Carlos ;

Canales, Miguel A. ;

Torres, Antonio ;

Moraleda, Jose M. ;

Panizo, Carlos ;

Jarque, Isidro ;

Palmero, Francisca ;

Hernandez, Miguel ;

Gonzalez-Barca, Eva ;

Lopez, Dulce ;

Caballero, Dolores .

HAEMATOLOGICA, 2014, 99 (03) :505-510

← 1 2 3 4 5 6 7 8 9 10 →